Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19

• Main Authors: Mohamad Shebley (Author), Stanley Wang (Author), Izna Ali (Author), Preethi Krishnan (Author), Rakesh Tripathi (Author), Joseph M. Reardon (Author), John Cafardi (Author), Galia Rahav (Author), Yoseph Caraco (Author), Jihad Slim (Author), Fadi Al Akhrass (Author), Mengjia Yu (Author), Yiran Hu (Author), Rosa De Abreu Ferreira (Author), Negar N. Alami (Author)
• Format: Book
• Published: Wiley, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract ABBV‐47D11 is a neutralizing monoclonal antibody that targets a mutationally conserved hydrophobic pocket distal to the ACE2 binding site of SARS‐CoV‐2. This first‐in‐human safety, pharmacokinetics, and antiviral pharmacodynamic assessment in patients with COVID‐19 provide an initial evalua...